FISCHER · NSE
Fischer Medical Ventures Limited
₹33.15
-0.45% (-₹0.15)
Prev. close
₹33.3
Volume
3,61,136
Delivery %
57.4%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Fischer Medical Ventures Limited
Fischer Medical Ventures Limited engages in the manufacture, distribution, leasing, and maintenance of medical equipment in India and internationally. Its product portfolio includes magnetic resonance imaging (MRI) systems; preventive health kiosks; e-health access points; software solutions; cancer, TB screening, and handheld x-ray; spincare technology; nutraceuticals; mental health solutions; contactless screening solutions; and CT scan systems, as well as preventive diagnostic devices and ancillary medical instruments. The company was formerly known as Fischer Chemic Limited and changed its name to Fischer Medical Ventures Limited in March 2024. Fischer Medical Ventures Limited was incorporated in 1993 and is headquartered in Chennai, India.
Details
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Ravindran Govindan LLB
Headquarters
Chennai
Employees
16
Website
fischermv.comExchange
View on NSE ↗Key stats
Market cap
₹2,268.81 Cr
P/E ratio (TTM)
73.7
Dividend yield
0.15%
EPS (TTM)
₹0.45
Beta (1Y · daily vs NIFTY 50)
0.59
Shares float
12.82 Cr
EPS · quarter ended Jun 2026
₹0.05
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Other assets floored at zero for years where fixed and current assets exceeded reported total assets.
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹17.95 L | ₹20.98 Cr | ₹110.70 Cr | ₹308.58 Cr | |
| EBITDA | — | — | ₹1.52 L | ₹2.36 Cr | ₹4.74 Cr | ₹54.66 Cr |
| — | — | ₹-3.65 L | ₹1.84 Cr | ₹1.48 Cr | ₹32.21 Cr | |
| Diluted EPS | — | — | ₹-0.21 | ₹1.08 | ₹0.01 | ₹0.45 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹25.36 L | ₹19.03 L | ₹0 | ₹86.00 Cr | ₹457.00 Cr | ₹672.00 Cr | |
| ₹23.28 L | ₹38.92 L | ₹57.17 L | ₹1.68 Cr | ₹85.37 Cr | ₹107.08 Cr | |
| Stockholders' equity | ₹31,000 | ₹-22.95 L | ₹17.00 L | ₹82.00 Cr | ₹338.00 Cr | ₹384.00 Cr |
Trade receivables, Fixed assets, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated. Inventory shows ₹0 for 2023-03-31 — this deck's own annual-report reading has no Inventory figure for this filer in any year shown (2023-03-31, 2021-03-31, 2022-03-31 alike); the ₹0 shown here comes from this filer's own reported data feed rather than this deck's own extraction, and is positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies) rather than a display default. 2021-03-31, 2022-03-31 have no Inventory figure reaching this deck at all — not shown as zero, not shown as positive — left blank rather than assumed to match the other years.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹-14.59 L | ₹-7.35 Cr | ₹-86.25 Cr | ₹-101.27 Cr | |
| Investing cash flow | — | — | ₹0 | ₹-31.39 Cr | ₹-125.36 Cr | ₹-5.22 Cr |
| — | — | ₹16.60 L | ₹37.06 Cr | ₹314.92 Cr | ₹14.11 Cr | |
| Capital expenditure | — | — | — | ₹-48.49 L | ₹-5.99 Cr | ₹-1.31 Cr |
| End cash position | — | — | ₹3.58 L | ₹94.83 L | ₹104.26 Cr | ₹11.69 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jun 25–Dec 25(5Q) | Mar 26–Jun 26(2Q) | Aug 26 |
|---|---|---|---|
| Promoter | 61.80% | 62.15% | 63.08% |
| Public | 38.20% | 37.85% | 36.92% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Fischer Medical Ventures Limited | ₹2,277.56 Cr | ₹33.15 | 74.0 | 5.93 | 8.4% | 0.28 | +178.8% | -70.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 26
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.